Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies

BACKGROUND: Pyrotinib, a novel irreversible tyrosine kinase inhibitor (TKI), has demonstrated promising antitumor activity to improve the overall response rate and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer (MBC). However, the survival data of pyrotinib o...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Xiuwen, Ma, Fei, Li, Qiao, Chen, Shanshan, Lan, Bo, Fan, Ying, Wang, Jiayu, Luo, Yang, Cai, Ruigang, Zhang, Pin, Li, Qing, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940415/
https://www.ncbi.nlm.nih.gov/pubmed/36803645
http://dx.doi.org/10.1186/s40364-023-00453-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940415/
https://www.ncbi.nlm.nih.gov/pubmed/36803645
http://dx.doi.org/10.1186/s40364-023-00453-0

Ejemplares similares